| 000 | 01865 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250516051609.0 | ||
| 264 | 0 | _c20120206 | |
| 008 | 201202s 0 0 eng d | ||
| 022 | _a1095-953X | ||
| 024 | 7 |
_a10.1016/j.nbd.2011.06.020 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aIdan-Feldman, Anat | |
| 245 | 0 | 0 |
_aDavunetide (NAP) as a preventative treatment for central nervous system complications in a diabetes rat model. _h[electronic resource] |
| 260 |
_bNeurobiology of disease _cDec 2011 |
||
| 300 |
_a327-39 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aCaspase 3 _xmetabolism |
| 650 | 0 | 4 |
_aCentral Nervous System Diseases _xetiology |
| 650 | 0 | 4 |
_aCognition Disorders _xdrug therapy |
| 650 | 0 | 4 |
_aDiabetes Mellitus, Experimental _xcomplications |
| 650 | 0 | 4 | _aDisease Models, Animal |
| 650 | 0 | 4 |
_aLectins _xmetabolism |
| 650 | 0 | 4 |
_aMagnetic Resonance Imaging _xmethods |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMaze Learning _xdrug effects |
| 650 | 0 | 4 |
_aMental Disorders _xdrug therapy |
| 650 | 0 | 4 |
_aNeuroprotective Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aOligopeptides _xtherapeutic use |
| 650 | 0 | 4 |
_aPhosphopyruvate Hydratase _xmetabolism |
| 650 | 0 | 4 | _aRats |
| 650 | 0 | 4 | _aRats, Sprague-Dawley |
| 650 | 0 | 4 |
_aReaction Time _xdrug effects |
| 650 | 0 | 4 | _aSocial Behavior |
| 650 | 0 | 4 |
_aSpace Perception _xdrug effects |
| 650 | 0 | 4 |
_aSynaptophysin _xmetabolism |
| 650 | 0 | 4 | _aTime Factors |
| 700 | 1 | _aSchirer, Yulie | |
| 700 | 1 | _aPolyzoidou, Eleni | |
| 700 | 1 | _aTouloumi, Olga | |
| 700 | 1 | _aLagoudaki, Roza | |
| 700 | 1 | _aGrigoriadis, Nikolaos C | |
| 700 | 1 | _aGozes, Illana | |
| 773 | 0 |
_tNeurobiology of disease _gvol. 44 _gno. 3 _gp. 327-39 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.nbd.2011.06.020 _zAvailable from publisher's website |
| 999 |
_c21072544 _d21072544 |
||